Structural analysis of human KDM5B guides histone demethylase inhibitor development.

Autor: Johansson C; Structural Genomics Consortium, University of Oxford, Headington, UK.; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Velupillai S; Structural Genomics Consortium, University of Oxford, Headington, UK., Tumber A; Structural Genomics Consortium, University of Oxford, Headington, UK.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Szykowska A; Structural Genomics Consortium, University of Oxford, Headington, UK., Hookway ES; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Nowak RP; Structural Genomics Consortium, University of Oxford, Headington, UK.; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Strain-Damerell C; Structural Genomics Consortium, University of Oxford, Headington, UK., Gileadi C; Structural Genomics Consortium, University of Oxford, Headington, UK., Philpott M; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Burgess-Brown N; Structural Genomics Consortium, University of Oxford, Headington, UK., Wu N; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Kopec J; Structural Genomics Consortium, University of Oxford, Headington, UK., Nuzzi A; Structural Genomics Consortium, University of Oxford, Headington, UK.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Steuber H; Bayer Healthcare Pharmaceuticals, Berlin, Germany., Egner U; Bayer Healthcare Pharmaceuticals, Berlin, Germany., Badock V; Bayer Healthcare Pharmaceuticals, Berlin, Germany., Munro S; Department of Oncology, University of Oxford, Oxford, UK., LaThangue NB; Department of Oncology, University of Oxford, Oxford, UK., Westaway S; Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Stevenage, UK., Brown J; Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Stevenage, UK., Athanasou N; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK., Prinjha R; Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Stevenage, UK., Brennan PE; Structural Genomics Consortium, University of Oxford, Headington, UK.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Oppermann U; Structural Genomics Consortium, University of Oxford, Headington, UK.; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK.
Jazyk: angličtina
Zdroj: Nature chemical biology [Nat Chem Biol] 2016 Jul; Vol. 12 (7), pp. 539-45. Date of Electronic Publication: 2016 May 23.
DOI: 10.1038/nchembio.2087
Abstrakt: Members of the KDM5 (also known as JARID1) family are 2-oxoglutarate- and Fe(2+)-dependent oxygenases that act as histone H3K4 demethylases, thereby regulating cell proliferation and stem cell self-renewal and differentiation. Here we report crystal structures of the catalytic core of the human KDM5B enzyme in complex with three inhibitor chemotypes. These scaffolds exploit several aspects of the KDM5 active site, and their selectivity profiles reflect their hybrid features with respect to the KDM4 and KDM6 families. Whereas GSK-J1, a previously identified KDM6 inhibitor, showed about sevenfold less inhibitory activity toward KDM5B than toward KDM6 proteins, KDM5-C49 displayed 25-100-fold selectivity between KDM5B and KDM6B. The cell-permeable derivative KDM5-C70 had an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels. The selective inhibitor GSK467 exploited unique binding modes, but it lacked cellular potency in the myeloma system. Taken together, these structural leads deliver multiple starting points for further rational and selective inhibitor design.
Databáze: MEDLINE
Externí odkaz: